Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genomics and Epigenomics of Pneumococcal Vaccines in the Elderly
NCT03104075Phase 4Completed
- Sponsor
- The Jackson Laboratory
- Start
- Apr 2017
- Primary completion
- Dec 2019
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of Prevnar 13, 23-valent pneumococcal polysaccharide vaccine in pneumonia, pneumococcal infection, sponsored by The Jackson Laboratory. Started Apr 2017; status: completed.
02
Drugs
Prevnar 1323-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumoniapneumococcal infection
Beyond the preview
Go deeper on NCT03104075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03104075.